ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

ClinicalTrials.gov ID: NCT03939689

Public ClinicalTrials.gov record NCT03939689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in mCRPC Patients Who Are 18F-DCFPyL PSMA-avid, Chemotherapy-naïve, and Progressed on Abiraterone (ARROW )

Study identification

NCT ID
NCT03939689
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Enrollment
120 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 29, 2019
Primary completion
Sep 20, 2023
Completion
Sep 23, 2024
Last update posted
Oct 13, 2025

2019 – 2024

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
18
Facility City State ZIP Site status
City of Hope Duarte California 91010
VA Greater Los Angeles Healthcare System Los Angeles California 90073
UCLA Los Angeles California 90095-7370
Hoag Family Cancer Institute Newport Beach California 92663
VA Palo Alto Healthcare System Palo Alto California 94303
Medstar Georgetown University Hospital Washington D.C. District of Columbia 20007
The University of Chicago Chicago Illinois 60637
University of Iowa Iowa City Iowa 52242
Tulane Medical School New Orleans Louisiana 70112
University of Maryland Baltimore Maryland 21201
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109
Washington University School of Medicine St Louis Missouri 63110
SUNY Upstate Medical University Syracuse New York 13210
University of Pennsylvania Philadelphia Pennsylvania 19104
LifeSpan Cancer Institute Providence Rhode Island 09206
Medical University of South Carolina Charleston South Carolina 29425
University of Texas MD Anderson Cancer Center Houston Texas 77030
University of Virginia Cancer Center Charlottesville Virginia 22908
Virginia Mason Medical Center Seattle Washington 98101
University of Washington - Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03939689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03939689 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →